Dr. Ahmed El Sawah
CO-Founder and CEO
THIRD EYE PHARMA
Across the history of the pharmaceutical industry, medications intended for the treatment of chronic diseases were and still are a major challenge. They are so important for the improvement of the patients’ quality of life and in the reduction of their disabilities; so they could contribute effectively in their communities.
Being driven by this though provoked the imagination of Alia Group founders the holding company of Third Eye pharmaceuticals to bring to the global healthcare markets innovative treatment technologies that could bridge the gaps in the current treatment options aiming to treat chronic diseases.
One such challenge was in the chronic wound care management, as we were seeking to secure a comprehensive treatment solution that could guarantee proper natural healing for chronic non-healing wounds, the thing that could save hundreds of thousands or even millions of patients’ limbs from amputation every year, the thing that we were successful at with the introduction of our first innovative technology solution, Tetrasilver Technology, which has been able to provide a never seen before wound healing experience for the medical professionals and patients all along. This innovative treatment solution was the prized pinnacle of years of research and development by our partners from the United States of America to present it to the global healthcare market.
Having mentioned that, Third Eye will continue to support innovative solutions in the segment of wound care management in alliance with major wound care centers in the USA as well as other centers located locally and regionally.
With regards to other chronic diseases, we are currently in the development phase to introduce another patented innovation for the treatment of patients suffering from Psoriasis to provide a cost effective,swift and permanent second to none treatment for those suffering patients worldwide.